Enko Dietmar, Wallner Franz, von-Goedecke Achim, Hirschmugl Christa, Auersperg Vinzenz, Halwachs-Baumann Gabriele
Department of Laboratory Medicine, Central Hospital Steyr, Sierningerstraße 170, 4400 Steyr, Austria.
Anemia. 2013;2013:641876. doi: 10.1155/2013/641876. Epub 2013 Mar 27.
The aim of this study was to evaluate a laboratory-guided therapeutic algorithm of preoperative anemia. 335 patients with elective hip or knee arthroplasty were included in this retrospective before-after study. Group I (n = 101) underwent conventional preoperative procedures before algorithm implementation. Group II (n = 234) underwent algorithm-guided preoperative anemia management. A hemoglobin-level of 13 g/dL was the therapeutic cut-off for men and women. Reticulocyte hemoglobin content (CHr) and soluble transferrin receptor (sTfR)/log ferritin ratio were used in the form of the Thomas plot. Iron deficiency (ID) was substituted with 1000 mg iron intravenous (i.v.) and 10000 international units (I.U.) of erythropoiesis-stimulating agent (ESA) subcutaneous (s.c.) or i.v., anemia of chronic disease (ACD) (without functional ID) with 40000 I.U. ESA s.c. or i.v and additionally 200 mg iron i.v. Substituted anemic patients in Group II (n = 32) showed a distinctly higher preoperative (Hb-median 13 versus 11.95 g/dL) (P < 0.01) and postoperative (Hb-median 9.75 versus 9.0 g/dL) (P < 0.05) Hb level compared with untreated anemic patients in Group I (n = 24). In Group II red blood cell (RBC) units (35 units/234 patients) were reduced by 44% compared with Group I (27 units/101 patients). Algorithm-guided preoperative anemia management raises perioperative Hb-level and reduces blood use.
本研究旨在评估一种术前贫血的实验室指导治疗方案。335例行择期髋关节或膝关节置换术的患者纳入了这项回顾性前后对照研究。第一组(n = 101)在方案实施前接受常规术前程序。第二组(n = 234)接受方案指导的术前贫血管理。血红蛋白水平13 g/dL为男性和女性的治疗切点。采用托马斯图形式使用网织红细胞血红蛋白含量(CHr)和可溶性转铁蛋白受体(sTfR)/铁蛋白对数比值。缺铁(ID)用1000 mg静脉注射铁剂和10000国际单位(I.U.)皮下(s.c.)或静脉注射(i.v.)促红细胞生成素(ESA)替代,慢性病贫血(ACD)(无功能性ID)用40000 I.U.皮下或静脉注射ESA以及另外200 mg静脉注射铁剂替代。第二组中替代治疗的贫血患者(n = 32)与第一组中未治疗的贫血患者(n = 24)相比,术前(血红蛋白中位数13对11.95 g/dL)(P < 0.01)和术后(血红蛋白中位数9.75对9.0 g/dL)(P < 0.05)血红蛋白水平明显更高。与第一组(27单位/101例患者)相比,第二组红细胞(RBC)单位用量(35单位/234例患者)减少了44%。方案指导的术前贫血管理可提高围手术期血红蛋白水平并减少血液使用。